Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.90
- Piotroski Score 2.00
- Grade Buy
- Symbol (KALV)
- Company KalVista Pharmaceuticals, Inc.
- Price $10.16
- Changes Percentage (8.95%)
- Change $0.84
- Day Low $9.32
- Day High $10.22
- Year High $16.88
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $28.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.12
- Trailing P/E Ratio -3.74
- Forward P/E Ratio -3.74
- P/E Growth -3.74
- Net Income $-126,644,000
Income Statement
Quarterly
Annual
Latest News of KALV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ipswich agree season-long loan deal for Kalvin Phillips from Manchester City
England midfielder Kalvin Phillips is set to undergo a medical with Ipswich on Thursday for a season-long loan from Manchester City. The move aims to revive his career after a disappointing stint at C...
By The Guardian | 3 months ago -
The Briefing: Man City 4 Chelsea 2 -- Is there a way back for Kalvin Phillips? Can Oscar Bobb take his chance?
Manchester City concluded their U.S. tour with a 4-2 victory over Chelsea, led by Erling Haaland's early goals. Guardiola emphasizes team preparedness. Oscar Bobb's performance is praised. Analysis on...
By The New York Times | 3 months ago
